The Tissue and Pathology core B is directed by breast pathologist, Dr. Andrea Richardson. This shared resource core will provide fresh human breast tumor samples of each of the ER and HER2 immunophenotypes for generation of early passage transplantable human-in-mouse xenografts in collaboration with Dr. Brown. The tissue and pathology core will characterize the xenograft tumors and compare to the paired original human tumor for histomorphology, immunophenotype, and molecular (gene expression and mutation) profiling. These xenograft models will be used for studies proposed in projects 1, 2, 4 and 6. The core will provide fresh breast tissue from women without cancer (breast reductions) and from women with germline BRCA1 or BRCA2 mutation for isolation of epithelial progenitor cells for studies proposed in projects 2 and 5. The tissues collected are from women who provided informed consent to one of our research banking protocols that allows for collection of excess tissues from clinical specimens for research and for collection of and linkage to long term outcome data. In addition, the core will provide research pathology services to perform histopathology analysis of mouse tumor models in projects 3 and 4.

Public Health Relevance

The Tissue and Pathology Core provides tissues derived from women with normal or diseased breast for use in research within the PPG. We anticipate that the results derived from such tissue-based studies are more likely to reflect the actual human condition and that human tissue-based research will allow for a better understanding of the true pathogenesis of human breast cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA080111-16
Application #
8633713
Study Section
Special Emphasis Panel (ZCA1-RPRB-J (O1))
Project Start
2014-02-01
Project End
2019-01-31
Budget Start
2014-05-02
Budget End
2015-01-31
Support Year
16
Fiscal Year
2014
Total Cost
$23,107
Indirect Cost
$3,626
Name
Whitehead Institute for Biomedical Research
Department
Type
DUNS #
120989983
City
Cambridge
State
MA
Country
United States
Zip Code
02142
Bailey, Shannon T; Westerling, Thomas; Brown, Myles (2015) Loss of estrogen-regulated microRNA expression increases HER2 signaling and is prognostic of poor outcome in luminal breast cancer. Cancer Res 75:436-45
Hines, William C; Su, Ying; Kuhn, Irene et al. (2014) Sorting out the FACS: a devil in the details. Cell Rep 6:779-81
Yamamoto, Shoji; Wu, Zhenhua; Russnes, Hege G et al. (2014) JARID1B is a luminal lineage-driving oncogene in breast cancer. Cancer Cell 25:762-77
Jeselsohn, Rinath; Yelensky, Roman; Buchwalter, Gilles et al. (2014) Emergence of constitutively active estrogen receptor-? mutations in pretreated advanced estrogen receptor-positive breast cancer. Clin Cancer Res 20:1757-67
Lu, Haihui; Clauser, Karl R; Tam, Wai Leong et al. (2014) A breast cancer stem cell niche supported by juxtacrine signalling from monocytes and macrophages. Nat Cell Biol 16:1105-17
Pathania, Shailja; Bade, Sangeeta; Le Guillou, Morwenna et al. (2014) BRCA1 haploinsufficiency for replication stress suppression in primary cells. Nat Commun 5:5496
Hu, Yiduo; Petit, Sarah A; Ficarro, Scott B et al. (2014) PARP1-driven poly-ADP-ribosylation regulates BRCA1 function in homologous recombination-mediated DNA repair. Cancer Discov 4:1430-47
McAllister, Sandra S; Weinberg, Robert A (2014) The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis. Nat Cell Biol 16:717-27
Hill, Sarah J; Rolland, Thomas; Adelmant, Guillaume et al. (2014) Systematic screening reveals a role for BRCA1 in the response to transcription-associated DNA damage. Genes Dev 28:1957-75
Hill, Sarah J; Clark, Allison P; Silver, Daniel P et al. (2014) BRCA1 pathway function in basal-like breast cancer cells. Mol Cell Biol 34:3828-42

Showing the most recent 10 out of 89 publications